Target intelligence / Profile preview

RNA, U6 small nuclear 405, pseudogene (RNU6-405P)

Target
RNU6-405P
Molecular classification
Other (Pseudogene), Non-coding RNA pseudogene
01

Overview

RNU6-405P encodes a **pseudogene** of the U6 small nuclear RNA (snRNA) family. Pseudogenes are genomic DNA sequences similar to normal genes but generally nonfunctional: they have lost protein-coding or RNA activity due to disabling mutations such as frameshifts or premature stop codons. The canonical U6 snRNA is a critical component of the spliceosomal machinery in eukaryotes, directly involved in pre-mRNA splicing as part of the U6 ribonucleoprotein. However, RNU6-405P does not produce functional snRNA and is annotated as nonfunctional by major genome databases. Pseudogenes can sometimes participate in regulatory functions, but specific activity for RNU6-405P has not been described. No disease association, biomarker role, or drug interaction is reported for RNU6-405P. In summary, **RNU6-405P is not a druggable target** and represents a genetically annotated pseudogene related to the highly conserved and functionally critical U6 snRNA involved in splicing in eukaryotic cells, but lacks functional activity as either an RNA molecule or a therapeutic target.

Other names
RNU6-405PRNA, U6 small nuclear 405, pseudogene
02

Mechanism of action

Not applicable; there are no drugs that target RNU6-405P, nor any established mechanism of action as a therapeutic target

03

Biological functions

None established for RNU6-405P as it is annotated as a pseudogene.Pseudogenes can sometimes play RNA-level regulatory roles, such as acting as competing endogenous RNAs (ceRNAs) or antisense regulators, but no specific biological function is documented for RNU6-405P itself.
04

Disease associations

None confirmed for RNU6-405P.Generally, pseudogenes can be involved in cancer and other disease processes via regulatory mechanisms, but RNU6-405P does not have documented implications in disease.
05

Safety considerations

None directly related to RNU6-405P. Safety concerns are irrelevant as it is not considered a therapeutic or functional molecular target.
06

Interacting drugs

None. Pseudogenes such as RNU6-405P are not known drug targets and do not interact with drugs.
07

Biomarkers

None. There is no evidence for RNU6-405P as a biomarker for disease or patient selection.

Beyond the preview

Go deeper on RNA, U6 small nuclear 405, pseudogene (RNU6-405P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 405, pseudogene (RNU6-405P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call